If you want to invest in individual companies to take advantage of long-term post-pandemic trends, this is probably the time to make your moves, as equity markets are forward-looking.

What follows are the analysts’ expected winners and losers among stocks traded in the U.S.

Potential post-COVID-19 winners

The Jefferies analysts listed these 12 U.S.-traded companies as “winners” in the post-pandemic environment:

You can click on the tickers for more about each company.

You will need to scroll the table to see all the data.

Potential post-COVID-19 losers

Here are the five U.S.-traded stocks included on the analysts’ list of expected “losers” from trends during and after the coronavirus pandemic:

The trends that drive the stock picks

Health services

For health-services companies, the analysts pointed to a trend that those with foresight may have identified before the terrible events of 2020: “Asset-heavy, inpatient-focused companies are likely to be at a disadvantage to leaner peers that are more focused on outpatients, diagnostic testing and using big data post-COVID.”

Who wouldn’t want to stay out of a nursing home or a hospital?

The analysts highlighted strengthened regulations leading to permanently higher costs for care in facilities, and also pointed to increased use of predictive diagnostics and telemedicine, as well as “sector disruption in technology and value-based care models.”

Read:Our hospitals need a bailout to cure their coronavirus-induced financial crisis

• Amedisys Inc. AMED, -0.83%, Encompass Health Corp. EHC, -4.08% and LHC Group Inc. LHCG, +1.93% were all listed as expected winners from the accelerated shift to in-home care.

• As the top provider of Medicaid-managed care services, Centene Corp. CNC, -1.17% was listed as an obvious beneficiary from massive U.S. unemployment.

• Jefferies calls Cerner Corp. CERN, -3.24% the “No. 2 player” in health-care information technology in the U.S.; the company is participating in the federal government’s systems rebuilds for the Department of Defense and the Department of Veterans Affairs.

• Teladoc Health Inc. TDOC, -3.39% is a clear winner already, with the critically important move toward telemedicine. But Jefferies rates the stock a “hold” because it has already risen 128% this year.

• CVS Health Corp. CVS, -0.76% and Walgreens Boots Alliance Inc. WBA, -2.82% were listed as “losers” because reductions in visits to doctors’ offices during past recessions led to “reduced demand for non-chronic prescriptions dispensed at retail pharmacies.”

Medical technology and tools

For medical technology, the Jefferies analysts cited “pent-up demand” for procedures and treatment in clinics, as well as increased “disease surveillance” and outpatient treatment.

• DexCom Inc. DXCM, -2.50% was listed as a winner from the industry move toward remote glucose monitoring for diabetes patients.

• Hologic Inc. HOLX, -1.74%, Bio-Rad Laboratories Inc. BIO, -1.87%, Danaher Corp. DHR, -0.89% and Thermo Fisher Scientific Inc. TMO, -2.54% were all listed as winners from high demand for testing services.

• Henry Schein Inc. HSIC, -4.34% and Patterson Cos. PDCO, -5.72% were listed as losers from reduced demand for dental devices.